·PIB·15 marks·250–350 wordsPolityS&T

Discuss the implications of making central permission a precondition for state manufacturing licences for antimicrobials, for drug regulation and cooperative federalism.

New · District CollectorCan you hold the district for 72 hours?Floods, a heatwave, an outbreak, a grievance queue. Take the decisions, see the consequences.Play →
In this answer
  1. Implications for drug regulation
  2. Implications for cooperative federalism

The Health Ministry's draft G.S.R. 983(E) would add antimicrobials to the "New Drug" definition in Rule 2(1)(w)(v), NDCT Rules, 2019. A manufacturer would then need Central Licensing Authority (CLA) permission before a State Licensing Authority (SLA) can issue a manufacturing licence [1]. This strengthens quality control against AMR, but it also changes the balance between the Centre and the States in a shared area of regulation.

Implications for drug regulation

  • Scientific checks before licensing: BA/BE and stability studies become mandatory. This closes a gap where licences were being granted without adequate scrutiny [1].
  • Containing AMR: substandard antimicrobials give patients too small a dose, which helps resistant microbes survive. The move fits the One Health commitment in the G20 New Delhi Leaders' Declaration [1].
  • One standard everywhere: the same quality benchmark applies in every state instead of differing state practices.
  • Capacity concern: in 2012, a Parliamentary Standing Committee found 31 new drugs approved without trials on Indian patients. The Ministry could produce safety reports (PSURs) for only 8 of 42 drugs it was asked about [3]. A central gate only works if CDSCO has enough staff.
  • Limits: the check happens once, at licensing, so poor batches made later can still reach the market. Compliance costs and delays may also hit small manufacturers.

Implications for cooperative federalism

  • Centralisation: States have traditionally issued manufacturing licences. A central step placed before them shifts effective control to the Centre, and it is being done through delegated legislation rather than an Act of Parliament [1].
  • Why the Centre has a case: SLAs licensed many FDCs without DCGI approval even though FDCs were already "new drugs" [2]. The Kokate Committee (2014) review led to a ban on 344 FDCs in 2016, which companies challenged in High Courts [4]. 328 more were banned in 2018 [2], and 16 more, including some antibiotic combinations, in 2026 under Section 26A after a Supreme Court-directed review [5]. A Rajya Sabha committee had earlier found that licensing was not uniform between the Centre and the States [6].
  • Layered, not taken over: the SLA still issues the licence [1]. The Centre adds a check before it but does not replace the States, and the 30-day consultation window gives States a voice [1].

Overall, the precondition trades some State autonomy for the same scientific checks everywhere, against a real public-health threat. To work, it needs a stronger CDSCO, a shared Centre–State registry that matches every licence to a prior central permission, and targeted market testing of antimicrobials. Done this way, the measure supports Article 47 and SDG 3 while keeping federalism cooperative.

Sources

  1. 1Union Health Ministry Proposes Amendment to New Drugs and Clinical Trials Rules, 2019 to Bring Antimicrobials under Central Regulatory Oversight, PIBG.S.R. 983(E), Rule 2(1)(w)(v), CLA→SLA sequence, BA/BE and stability studies, One Health/G20, 30-day window
  2. 2Prohibition and restriction of manufacture, sale and distribution of Fixed Dose Combinations (FDCs), PIBSLAs licensing FDCs without DCGI approval; 328 FDCs banned in 2018
  3. 3Lapses in the process of drug approval in India, PRS Legislative Research2012 Standing Committee: 31 drugs approved without Indian trials; PSURs for 8 of 42
  4. 4Banning of FDC Drugs, PIBKokate Committee; 344 FDCs banned in 2016; High Court challenges
  5. 5Union Ministry of Health and Family Welfare Prohibits Manufacture, Sale and Distribution of 16 Fixed Dose Combinations (FDCs) in Public Interest, PIB16 FDCs banned under Section 26A after a Supreme Court-directed review, including antibiotic combinations
  6. 6Rajya Sabha Standing Committee Report on the Drugs and Cosmetics (Amendment) Bill, 2007, via PRSlicensing not uniform between Centre and States
Practice
7 questions on this item
Check the answer for each question, or reveal all at once.
Practice MCQs →

More from this note

More on Polity